Phase II study of ruxolitinib, a selective JAK1/2...

npj Breast Cancer 2018 / 12 Vol. 4; Iss. 1

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

Stover, Daniel G., Gil Del Alcazar, Carlos R., Brock, Jane, Guo, Hao, Overmoyer, Beth, Balko, Justin, Xu, Qiong, Bardia, Aditya, Tolaney, Sara M., Gelman, Rebecca, Lloyd, Maxwell, Wang, Yu, Xu, Yaomin
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
4
Language:
english
Journal:
npj Breast Cancer
DOI:
10.1038/s41523-018-0060-z
Date:
December, 2018
File:
PDF, 2.95 MB
english, 2018
Conversion to is in progress
Conversion to is failed